| Aug 8 |
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
|
| Aug 8 |
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
|
| Aug 7 |
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
|
| Aug 7 |
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?
|
| Aug 2 |
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
|
| Aug 1 |
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
|
| Aug 1 |
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
|
| Jul 31 |
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
|
| Jul 30 |
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
|
| Jul 25 |
Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?
|
